JELD‑WEN to cut 850 jobs and trims 2025 outlook after deep Q3 loss; Europe business under strategic review

6 November 2025

Date: Nov. 6, 2025

Key takeaways

Door-and-window maker JELD‑WEN (NYSE: JELD) will eliminate ~850 roles (about 11% of its North America and corporate workforce) by year‑end 2025. ^[1]
Q3 2025 results: revenue $809.5M (‑13.4% YoY); net loss $367.6M (including a non‑cash goodwill impairment). Adjusted EBITDA $44.4M (5.5% margin). ^[2]
Company lowered full‑year 2025 guidance to $3.1B–$3.2B revenue and $105M–$120M adjusted EBITDA; expects ~$10M–$20M in workforce‑reduction costs and ~$45M operating cash outflow for the year. ^[3]
Local impact: cuts include roles in Charlotte, where JELD‑WEN is headquartered. ^[4]
Market reaction: shares fell after the announcement as investors digested the reduced outlook and job cuts. ^[5]

What’s new today (Nov. 6)

Following Monday’s earnings release, JELD‑WEN confirmed it will shed ~850 positions across North America and corporate functions and is reviewing strategic alternatives for its Europe segment. The workforce actions, slated to be completed by the end of 2025, are part of a broader cost‑reset amid weaker demand and price‑cost pressure. ^[6]

Charlotte’s local press reports the reductions will include positions in the Charlotte area, adding a regional dimension to the restructuring at the company’s headquarters. ^[7]

The numbers: Q3 at a glance

Revenue:$809.5M (‑13.4% YoY), driven by a 10% decline in core revenue and the impact of the Towanda divestiture (‑5%), partially offset by +2% FX.
Net loss:$367.6M (‑$4.30/share), reflecting a $196.9M non‑cash goodwill impairment and $122.3M in tax special items.
Adjusted EBITDA:$44.4M, margin 5.5% (down 320 bps YoY).
Segment detail:North America revenue $546.1M (‑19.4%) on softer volume/mix; Europe revenue $263.3M (+2.6%) on favorable FX despite softer core demand. ^[8]

The Associated Press likewise summarized the quarter as a loss‑making period with revenue at $809.5M and a net loss translating to ‑$4.30 per share. ^[9]

Guidance cut and cash outlook

Management lowered 2025 guidance to $3.1B–$3.2B revenue (core down 10%–13% YoY) and $105M–$120M adjusted EBITDA, citing a competitive pricing and volume environment. JELD‑WEN now expects an operating cash outflow of ~$45M in 2025, including $10M–$20M of workforce‑reduction costs. ^[10]

Strategy reset: Europe under review

As part of the transformation plan, the company initiated a strategic review of its Europe business—a portfolio move that could include divestiture, partnerships or other alternatives, according to the company’s release. ^[11]

How Wall Street is reacting

JELD‑WEN shares fell after the update as investors weighed job cuts, a lower outlook and the Europe review. Financial press coverage flagged the stock’s weakness on the news. ^[12]

Analyst context: a painful present, potential for a multi‑year turnaround

Equity research aggregators note a tough five‑year stretch—losses have grown ~78% annually—but also point to consensus models that project a sharp EPS rebound (~131% CAGR) over the next few years as cost actions flow through, even with only modest revenue growth. That optimistic scenario hinges on execution of the transformation and stabilization of end‑market demand. ^[13]

What it means for employees and the Carolinas

Who’s affected: approximately 850 positions across North America and corporate teams, with roles in Charlotte among those impacted. The company says decisions are designed to “align cost structure” and “improve efficiency.” ^[14]
Timing & costs: actions are targeted for completion by year‑end 2025; the company estimates $10M–$20M in related costs this year. ^[15]

The road ahead: 5 things to watch

Restructuring execution: cadence of severance, footprint changes, SKU rationalization and procurement savings versus guidance. ^[16]
Europe review outcome: potential sale or partnership could reshape the portfolio and balance sheet. ^[17]
North America demand: management cited weaker volume/mix; any turn in housing activity or repair‑and‑remodel could help margins. ^[18]
Margins vs. pricing: price‑cost dynamics remain a headwind; watch the adjusted EBITDA margin trajectory from 5.5%. ^[19]
Capital and cash: management’s ~$45M operating cash use guidance and any deleveraging or asset‑sale proceeds. ^[20]

Quick Q&A

Why is JELD‑WEN cutting jobs now?
Management says the reductions are needed to rebalance costs amid weaker demand and to support a multi‑year transformation, while it also reviews Europe for strategic options. ^[21]

How severe was Q3?
Revenue fell 13.4%, and the company posted a $367.6M net loss driven largely by a non‑cash goodwill impairment; adjusted EBITDA margin slid to 5.5%. ^[22]

Will Charlotte be affected?
Yes—the Charlotte Observer reports the cuts will include roles in Charlotte, where JELD‑WEN is headquartered. ^[23]

What’s the 2025 outlook now?
Revenue $3.1B–$3.2B, adjusted EBITDA $105M–$120M; operating cash flow expected to be ~$45M use, including $10M–$20M in workforce‑reduction costs. ^[24]

What are analysts modeling long‑term?
Some forecast a triple‑digit EPS growth rate over coming years if the turnaround sticks, but risks remain if volumes and pricing don’t stabilize. ^[25]

Sources

JELD‑WEN Q3 2025 news release and fact sheet (financials, guidance, restructuring). ^[26]
Charlotte Observer: local impact and Charlotte roles included in the headcount reduction. ^[27]
AP earnings snapshot for confirmation of revenue and per‑share loss. ^[28]
Barron’s/MarketWatch: coverage of stock reaction to the announcement. ^[29]
Simply Wall St: multi‑year loss trend and consensus turnaround forecasts. ^[30]

This article is intended for general news purposes and does not constitute investment advice.

References

1. s2.q4cdn.com, 2. s2.q4cdn.com, 3. s2.q4cdn.com, 4. www.charlotteobserver.com, 5. www.barrons.com, 6. s2.q4cdn.com, 7. www.charlotteobserver.com, 8. s2.q4cdn.com, 9. www.greenwichtime.com, 10. s2.q4cdn.com, 11. investors.jeld-wen.com, 12. www.barrons.com, 13. simplywall.st, 14. s2.q4cdn.com, 15. s2.q4cdn.com, 16. s2.q4cdn.com, 17. investors.jeld-wen.com, 18. s2.q4cdn.com, 19. s2.q4cdn.com, 20. s2.q4cdn.com, 21. s2.q4cdn.com, 22. s2.q4cdn.com, 23. www.charlotteobserver.com, 24. s2.q4cdn.com, 25. simplywall.st, 26. s2.q4cdn.com, 27. www.charlotteobserver.com, 28. www.greenwichtime.com, 29. www.barrons.com, 30. simplywall.st

Tags:

Marcin Frąckiewicz Latest posts

CEO of TS2 Space and founder of TS2.tech. Expert in satellites, telecommunications, and emerging technologies, covering trends in space, AI, and connectivity.

View all

Is Elevance Health a Hidden Opportunity After a 24.5% Drop in 2025?
November 6, 2025, 7:28 AM EST. Elevance Health has tumbled in 2025 amid policy shifts and broader healthcare-sector volatility, with a year-to-date drawdown and a longer 24.5% slide that has investors rethinking value. The piece weighs near- and long-term catalysts, noting that a high valuation score isn't translating into certainty as government program changes loom for managed care. The core takeaway is a rigorous DCF assessment, which, using current free cash flow of $3.6B and projected growth, yields an intrinsic value around $1,090.84 per share-roughly 71% above current prices, signaling undervaluation. Still, equity investors should monitor the PE ratio, competitive dynamics, and policy risk, which could affect how quickly this perceived bargain translates into realized gains.
Inflammation Biotech Evommune Starts NYSE Trading in $150M IPO
November 6, 2025, 7:24 AM EST. Evommune is heading to the NYSE with a $150 million IPO to fund two clinical-stage assets. The Palo Alto biopharma is offering 9.3 million shares at $16 each, pricing in the $15-$17 range. Gross proceeds are $150 million, potentially rising by about $22.5 million if underwriters exercise their option for an additional 1.4 million shares. Trading under the ticker EVMN could begin today. The company plans to use the funds to advance two phase 2 programs, including EVO756, an oral MRGPRX2 antagonist being studied for CSU and atopic dermatitis (AD). Topline data for CSU from a phase 2 study showed 93% responses at four weeks. Data for AD topline in H2 2026. Evommune priced amid a broader biotech IPO backdrop as MapLight Therapeutics went public last week.
Arm Holdings Stock Surges on Q2 Beat, Strong AI Demand Lifts Outlook
November 6, 2025, 7:22 AM EST. Arm Holdings (ARM) stock jumps about 5-6% in pre-market trading after reporting a Q2 beat that topped revenue and earnings estimates and issuing stronger Q3 guidance. The company posted revenue of $1.14 billion, up 34% year over year, and EPS of $0.22, exceeds consensus of $0.13. Arm also raised its quarterly revenue guide to about $1.23 billion versus the $1.10 billion expected. Royalty revenue reached a record $620 million, up 21%, led by data centers, automotive, and IoT, with hyperscalers like Google, Amazon, and Microsoft boosting Arm-based deployments. Licensing revenue rose 56% to $515 million. The AI infrastructure buildout underscores demand for Arm's energy-efficient designs, and management hints at potential in-house chip development beyond licensing.
Capital One Stock Prediction: Analysts See Up to 29% Upside by 2027 on Discover Acquisition
November 6, 2025, 7:20 AM EST. Capital One (NYSE: COF) trades around $221 with an average target near $260, implying ~18% upside. Targets span $290 (high) and $210 (low), with a median near $258 and a mix of 14 Buys, 3 Outperforms, and 6 Holds. Growth projections call for revenue up about 19% annually through 2027, supported by operating margins near 48% and a forward multiple around 9.7x. A guided model points to ~$285/share by 2027, or about 29% total upside (12% annualized). The story centers on the Discover acquisition, expanded payments network, and stable credit trends amid solid consumer spending, though conviction remains modest and upside depends on continued earnings growth and credit stability.
Three Stocks Added to Zacks Rank #5 Strong Sell List on Nov. 6: ACHC, FWRD, CENX
November 6, 2025, 7:18 AM EST. Three names were added to Zacks Rank #5 (Strong Sell) today: Acadia Healthcare (ACHC), Forward Air (FWRD), and Century Aluminum (CENX). For the current year, earnings estimates were revised downward by 3.2%, 12%, and 11.7% over the last 60 days, respectively. The update reinforces the Strong Sell roster per Zacks research. The piece also highlights a separate feature on a stock most likely to double and a prompt to download Zacks' top stock ideas.